Combined Hyperlipidemia, Primary Hypercholesterolemia
Conditions
Brief summary
This clinical trial is an open, randomized, 2-group, 2-period, fasting, single-dose, crossover study to evaluate the bioequivalence of Crecheck Tablet 2.5 mg (Rosuvastatin Calcium) of Hanlim Pharm. Co., Ltd. and Crestor Tablet 5 mg (Rosuvastatin Calcium) of AstraZeneca Korea Co., Ltd. in healthy adult subjects.
Detailed description
This study is to compare and evaluate the safety and pharmacokinetic characteristics of Hanlim Pharm. Co., Ltd.'s Crecheck Tablet 2.5 mg (Rosuvastatin Calcium) as the test drug and AstraZeneca Korea Co., Ltd.'s Crestor Tablet 5 mg (Rosuvastatin Calcium) as the reference drug in healthy adults.
Interventions
DRUGCrecheck Tablet 2.5 mg
2 tablets orally once a day
DRUGCrestor Tablet 5 mg
1 tablet orally once a day
Sponsors
Hanlim Pharm. Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Individuals aged 19 years or older at the time of screening 2. Individuals with no clinically significant congenital or chronic diseases and no pathological symptoms or findings based on medical examinations (such as EEG, ECG, chest and gastric endoscopy, or gastrointestinal radiology tests, if necessary) 3. Individuals deemed suitable for the study based on screening tests (e.g., hematology, blood chemistry, serology, and urinalysis) as determined by the principal investigator (or a designated sub-investigator) 4. Individuals with a Body Mass Index (BMI) between 18.0 and 30.0 (BMI calculation: weight (kg) / height (m)²) 5. Individuals who have received and understood a thorough explanation of the study's purpose, content, investigational drug characteristics, and potential adverse events, and have voluntarily decided to participate and agreed in writing to comply with the study requirements during the trial period 6. Individuals who agree to use medically recognized contraceptive methods\* (excluding hormonal contraceptives) to avoid pregnancy from the first administration of the investigational drug until one week after the last administration \* Medically recognized contraceptive methods: intrauterine devices (IUD, IUS), vasectomy, tubal ligation, and combined barrier methods (male condoms, female condoms, cervical caps, diaphragms, sponges, etc.), or if using spermicides, combined use of two or more barrier methods
Exclusion criteria
1. Individuals who have taken enzyme-inducing or inhibiting drugs such as barbiturates within 30 days before the start of the study (first dosing day) or medications that might interfere with the study within 10 days before the start of the study (first dosing day) 2. Individuals who have engaged in excessive alcohol consumption within one month before the start of the study (first dosing day) * For men, more than an average of 21 drinks per week * For women, more than an average of 14 drinks per week (One drink: 45 mL of distilled spirits or 360 mL of beer or 150 mL of wine) 3. Individuals who have participated in clinical trials (including bioequivalence studies) and received investigational drugs within six months before the start of the study (first dosing day) 4. Individuals who have donated whole blood within 8 weeks or donated blood components within 2 weeks before the start of the study (first dosing day) 5. Individuals with a history of gastrointestinal surgery that may affect drug absorption 6. Patients with the following conditions: * Hypersensitivity to the components of this drug * Active liver disease, including unexplained persistent elevations in serum transaminases or serum transaminase levels exceeding three times the upper limit of normal * Myopathy * Concurrent use of cyclosporine * Severe renal impairment (creatinine clearance (CLcr) \< 30 mL/min) * Pregnant or lactating women, and women of childbearing potential not using adequate contraceptive methods * Patients prone to myopathy/rhabdomyolysis (contraindicated when administered at a 40 mg dose of this drug) * Moderate renal impairment (creatinine clearance \< 60 mL/min) * Hypothyroidism * A history or family history of hereditary muscle disorders * A history of muscle toxicity with other HMG-CoA reductase inhibitors or fibrates * Alcoholism * Situations where plasma concentrations may increase * Asian patients * Concurrent use of fibrates * Genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption, since this product contains lactose 7. Individuals with a history of mental illness 8. Individuals deemed unsuitable for this clinical trial for reasons other than the above inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Area under the plasma concentration versus time curve (AUC) | 48 hours | Concentration of rosuvastatin in plasma |
| Peak Plasma Concentration (Cmax) | 48 hours | Concentration of rosuvastatin in plasma |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| AUC∞ | 48 hours | Concentration of rosuvastatin in plasma |
| Time to Maximum Plasma Concentration (Tmax) | 48 hours | Concentration of rosuvastatin in plasma |
| Dissolution pattern by comparative dissolution test of Rosuvastatin | 48 hours | — |
| AUCt/AUC∞(%) | 48 hours | Concentration of rosuvastatin in plasma |
| Half Life (t1/2) | 48 hours | Concentration of rosuvastatin in plasma |
Countries
South Korea
Outcome results
None listed